Introduction Zongertinib (BI 1810631) has shown promising results in treating HER2-mutant non-small cell lung cancer (NSCLC), with a 71% response rate as presented at AACR 2025. This oral, HER2-selective tyrosine kinase inhibitor (TKI) offers a new option for patients with this challenging condition. In this post, we explore the Beamion LUNG-1 trial results, zongertinib’s clinical … Continue reading Zongertinib 71% ORR for HER2-Mutant NSCLC: Key Insights from AACR 2025